| Firm | Analyst | Phone | Type | Rating | |
|---|---|---|---|---|---|
|
Baird
|
Brian Skorney | ||||
|
Bank of America Securities
|
Tazeen Ahmad | ||||
|
Barclays
|
Eliana Merle | ||||
|
Bernstein
|
Will Pickering | ||||
|
BMO
|
Evan Seigerman | ||||
|
Canaccord Genuity
|
Whitney Ijem | ||||
|
Cantor Fitzgerald
|
Carter Gould | ||||
|
Citi
|
Geoff Meacham, Ph.D. | ||||
|
TD Cowen
|
Phil Nadeau, Ph.D. | ||||
|
Evercore ISI
|
Cory Kasimov | ||||
|
Goldman Sachs
|
Salveen Richter | ||||
|
Guggenheim Securities
|
Debjit Chattopadhyay, Ph.D. | ||||
|
HC Wainwright
|
Andrew Fein | ||||
|
Jefferies
|
Akash Tewari | ||||
|
J.P. Morgan
|
Jessica Fye | ||||
|
Leerink Partners
|
David Risinger | ||||
|
Maxim Group
|
Naz Rahman | ||||
|
Morgan Stanley
|
Terence Flynn, Ph.D. | ||||
|
Needham & Company
|
Joseph Stringer, Ph.D. | ||||
|
Oppenheimer
|
Jay Olson | ||||
|
Raymond James
|
Chris Raymond | ||||
|
RBC
|
Brian Abrahams, M.D. | ||||
|
Redburn Atlantic
|
Steve Chesney | ||||
|
Scotiabank
|
Louise Chen | ||||
|
Stifel
|
Paul Matteis | ||||
|
Truist Securities
|
Danielle Brill | ||||
|
UBS
|
Michael Yee | ||||
|
Wells Fargo
|
Mohit Bansal | ||||
|
William Blair
|
Myles Minter, Ph.D. | ||||
|
Wolfe Research
|
Andy Chen, Ph.D. |
Vertex Pharmaceuticals is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vertex Pharmaceuticals's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vertex Pharmaceuticals or its management. Vertex Pharmaceuticals does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.